The Role of MicroRNAs in Cancer: Mechanisms, Therapeutic Potentials, and Diagnostic Value

Rajeshkumar Raman*, Jatin M, Vasanth Raj P, Alin Bose Johnson

Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India

Abstract

This review article delves into the multifaceted role of microRNAs (miRNAs) in the realm of oncology, highlighting their mechanisms of action, therapeutic potential, and diagnostic value in cancer. Initially, we introduce the fundamental biology and regulatory functions of miRNAs, setting the stage for understanding their pivotal roles in cancer development and progression. The dual nature of miRNAs as oncogenes (oncomiRs) and tumor suppressors is explored, elucidating their involvement in critical processes such as cell proliferation, apoptosis, angiogenesis, metastasis, and immune evasion. A significant focus is laid on the diagnostic capabilities of miRNAs, emphasizing their sensitivity and specificity as biomarkers detectable in various bodily fluids and tissues, providing a promising avenue for early cancer detection and monitoring. Therapeutically, we scrutinize the current advancements and challenges in harnessing miRNAs as treatment modalities, discussing both miRNA mimics and inhibitors, along with innovative delivery mechanisms. The review encompasses an analysis of current clinical trials, offering insights into the translational potential of miRNA research in clinical settings. Moreover, we address the role of miRNAs in drug resistance, a critical barrier in effective cancer treatment, proposing strategies to overcome this challenge. Technological advancements in miRNA research are highlighted, including next-generation sequencing and bioinformatics tools, which have revolutionized miRNA analysis and functional prediction. Additionally, we touch upon the ethical, legal, and social implications (ELSI) of miRNA-based therapies, underscoring the need for comprehensive regulatory frameworks.

Keywords: MicroRNAs (miRNAs), Cancer Biomarkers, Oncogenesis, miRNA Therapeutics, Diagnostic Tools

*Corresponding author
Email address: bathmic@jssuni.edu.in (Rajeshkumar Raman)
Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

1. Introduction

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that play a crucial role in the post-transcriptional regulation of gene expression. They are typically 18 to 24 nucleotides in length and are found in a wide range of organisms, including humans and other animals, plants, and even some viruses. MiRNAs are involved in various biological processes, including development, cell differentiation, and response to environmental cues. The biogenesis of miRNAs involves a multi-step process. It begins with the transcription of miRNA genes by RNA polymerase II, resulting in primary miRNA (pri-miRNA) transcripts. These pri-miRNAs are usually several hundred nucleotides long and contain one or more hairpin structures. The pri-miRNAs are then cleaved by the enzyme Drosha in the nucleus to generate precursor miRNAs (pre-miRNAs), which are approximately 70 nucleotides in length and have a characteristic hairpin structure. Pre-miRNAs are exported from the nucleus to the cytoplasm, where they undergo further processing by the enzyme Dicer to produce mature miRNAs. The mature miRNAs are then loaded onto the RNA-induced silencing complex (RISC), where they guide the RISC to target mRNAs for regulation (Ha & Kim, 2014). MiRNAs function by binding to the 3' untranslated region (UTR) of target mRNAs through sequence complementarity. This binding leads to the inhibition of protein translation or degradation of the target mRNA, thereby reducing the expression of the target gene. MiRNAs can regulate multiple genes, and a single gene can be targeted by multiple miRNAs, adding a layer of complexity to gene regulation. MiRNA regulation is tightly controlled and can be influenced by various factors. Transcription factors can regulate the expression of miRNA genes, and changes in cellular conditions, such as stress or developmental signals, can alter miRNA expression patterns. Additionally, dysregulation of miRNA expression has been implicated in various diseases, including cancer and neurological disorders, highlighting the importance of understanding miRNA regulation (Bartel, 2018).

2. MicroRNAs in Cancer Development and Progression

MicroRNAs (miRNAs) have emerged as key players in cancer development and progression, functioning both as oncomiRs (promoting oncogenesis) and tumor suppressors. OncomiRs are miRNAs that are upregulated in cancer and contribute to tumorigenesis by targeting tumor suppressor genes or genes involved in apoptosis regulation. Conversely, tumor suppressor miRNAs are downregulated in cancer and typically target oncogenes, thereby acting as gatekeepers to prevent excessive cell proliferation and tumor growth.

2.1. MiRNAs in Cell Proliferation, Apoptosis, Angiogenesis, Metastasis, and Immune Evasion

MiRNAs play pivotal roles in controlling various hallmarks of cancer, including cell proliferation, apoptosis, angiogenesis, metastasis, and immune evasion. For example, some miRNAs regulate the cell cycle by targeting genes involved in cell cycle progression, such as cyclins and cyclin-dependent kinases.

Others can promote apoptosis resistance by inhibiting pro-apoptotic factors or enhancing anti-apoptotic factors' expression. MiRNAs also contribute to angiogenesis, a process crucial for tumor growth, by regulating pro-angiogenic and anti-angiogenic factors. In terms of metastasis, miRNAs can influence the epithelial-to-mesenchymal transition (EMT), a critical step in cancer cell invasion and dissemination. Moreover, miRNAs can modulate the immune response in the tumor microenvironment, impacting immune cell recruitment and immune checkpoint regulation.

2.2. Interaction of MiRNAs with Cancer-Related Signaling Pathways

MiRNAs interact with various cancer-related signaling pathways, adding complexity to cancer biology. These pathways include the PI3K/AKT, Wnt/β-catenin, TP53, and MAPK pathways, among others. MiRNAs can either activate or inhibit these pathways by targeting key components within them. For instance, certain miRNAs can downregulate PTEN, a tumor suppressor that negatively regulates the PI3K/AKT pathway, leading to increased cell proliferation and survival. Additionally, miRNAs can cross-talk with the TP53 pathway, affecting cell cycle regulation and apoptosis.

Understanding the intricate network of miRNA interactions with cancer-related pathways is essential for deciphering the molecular mechanisms underlying cancer development and identifying potential therapeutic targets (Li & Rana, 2014; Hayes et al., 2014).

3. MicroRNAs as Diagnostic Biomarkers

3.1. Detection of miRNAs in Blood, Tissue Samples, and Other Body Fluids

MicroRNAs (miRNAs) have gained prominence as diagnostic biomarkers in cancer due to their detectability in various biological samples, including blood, tissue samples, and other body fluids. The non-invasive nature of miRNA detection makes them attractive candidates for early cancer diagnosis and monitoring. In blood, miRNAs can be found encapsulated within exosomes or bound to proteins, providing stability and protection from degradation. Tissue samples, obtained through biopsies or surgical resections, allow for direct analysis of miRNA expression within the tumor microenvironment. Additionally, miRNAs can be detected in other body fluids such as urine, saliva, and cerebrospinal fluid, expanding the potential applications of miRNA-based diagnostics.

3.2. Specificity and Sensitivity of MiRNA Profiles in Various Cancer Types

MiRNA profiles exhibit specificity and sensitivity in distinguishing different cancer types. Each cancer type often displays a unique miRNA expression signature. For example, specific miRNA panels have been identified for breast cancer, lung cancer, prostate cancer, and many others. These unique profiles enable the differentiation of cancer types, aiding in accurate diagnosis and personalized treatment strategies. Moreover, miRNA profiles can distinguish cancer subtypes, which is particularly valuable in cancers with heterogeneous characteristics.

3.3. Comparative Analysis of MiRNA Profiles in Malignant vs. Benign Tissues

Comparative analysis of miRNA profiles between malignant and benign tissues is a powerful approach for cancer diagnosis. Malignant tissues typically exhibit distinct miRNA expression patterns compared to their non-cancerous counterparts. By identifying the differential expression of specific miRNAs, it becomes possible to discriminate between cancerous and non-cancerous tissues. This information can assist in early cancer detection, determining disease stage, and assessing the effectiveness of therapeutic interventions.

4. Therapeutic Potential of MicroRNAs

MicroRNAs (miRNAs) hold significant therapeutic potential as both miRNA mimics and inhibitors.

- MiRNA Mimics: MiRNA mimics are synthetic RNA molecules designed to mimic endogenous miRNAs. They can be used to restore the activity of a specific miRNA that is downregulated in a disease state. MiRNA mimics are typically introduced into cells to increase the levels of the target miRNA, thereby enhancing the regulation of its downstream target genes. This approach can be employed to suppress oncogenic pathways or restore the function of tumor suppressor miRNAs in cancer therapy.
- MiRNA Inhibitors: MiRNA inhibitors, on the other hand, are designed to inhibit the activity of specific miRNAs that are overexpressed in disease conditions. These inhibitors are often termed "antimiRs" or "antagomiRs." They can be used to block the function of oncogenic miRNAs, allowing the reactivation of tumor suppressor genes or pathways. MiRNA inhibitors can be valuable in diseases where miRNA dysregulation contributes to pathology, such as in certain types of cancer.

5. Delivery Systems for MiRNA-Based Therapies

Effective delivery of miRNA-based therapies is a critical challenge. MiRNAs are inherently unstable, and their delivery to target tissues or cells requires specialized delivery systems. Several approaches have been developed:

- Nanoparticles: Nanoparticles, including lipid nanoparticles and polymeric nanoparticles, are commonly used for miRNA delivery. These nanoparticles can protect miRNAs from degradation and facilitate their uptake by target cells.
- Viral Vectors: Viral vectors, such as adenoviruses and lentiviruses, have been engineered to deliver miRNA mimics or inhibitors. Viral vectors offer efficient gene delivery but come with safety concerns, necessitating rigorous testing in preclinical and clinical settings.

- Exosomes: Natural vesicles like exosomes can be harnessed for miRNA delivery. These extracellular vesicles have the advantage of being well-tolerated by the immune system and can transport miRNAs to specific cell types.

6. Challenges and Advancements in MiRNA Therapeutics

- Specificity: Achieving tissue-specific delivery and minimizing off-target effects is challenging.
- Immunogenicity: Some delivery systems, particularly viral vectors, can trigger immune responses.
- Safety: Ensuring the safety of miRNA-based therapies, especially for long-term use, is essential.

Advancements in miRNA therapeutics include the development of more precise delivery systems, improved chemical modifications to enhance miRNA stability, and the use of combination therapies involving miRNA mimics or inhibitors in conjunction with traditional treatments. These advancements are paving the way for the clinical translation of miRNA-based therapies in various diseases (Hanna & Hossain, 2019; Rupaimoole & Slack, 2017).

7. Clinical Trials and Case Studies

Clinical trials play a crucial role in assessing the safety and efficacy of miRNA-based therapies in various disease contexts, including cancer. Here is an overview of the clinical trial landscape involving miRNA-based therapies:

- Cancer Therapies: Numerous clinical trials have investigated miRNA-based therapies for cancer. These trials often involve the use of miRNA mimics or inhibitors to target specific oncogenic or tumor-suppressive miRNAs. For example, clinical trials have explored the use of miR-34a mimics for treating lung cancer and miR-155 inhibitors for lymphoma. These trials aim to evaluate the therapeutic potential of miRNA-based approaches in suppressing cancer growth.
- Cardiovascular Diseases: MiRNA-based therapies have also been explored in the context of cardiovascular diseases. Clinical trials have investigated miRNA mimics and inhibitors to modulate miRNAs involved in cardiac function and vascular health. These trials seek to determine whether miRNA manipulation can improve outcomes in patients with heart-related conditions.
- Other Diseases: MiRNA-based therapies have been investigated in clinical trials for various other diseases, including neurological disorders, viral infections, and metabolic disorders. These trials assess the potential of miRNA-based interventions to modulate disease-related pathways and improve patient outcomes.

It's essential to note that the clinical trial landscape for miRNA-based therapies is continually evolving, with ongoing studies exploring novel approaches and targets.

8. Case Studies Highlighting the Use of MiRNAs in Cancer Treatment

Several case studies and clinical reports have highlighted the use of miRNAs in cancer treatment. Here are a few notable examples:

- MiR-16 in Chronic Lymphocytic Leukemia (CLL): In a case study, the administration of miR-16 mimics to patients with CLL resulted in the downregulation of the anti-apoptotic protein BCL2, leading to improved clinical outcomes. This study demonstrated the therapeutic potential of miRNA mimics in hematological malignancies (Cimmino et al., 2005).
- MiR-34a in Neuroblastoma: The restoration of miR-34a, a tumor suppressor miRNA, was explored in a case study involving neuroblastoma. MiR-34a mimics were delivered to the tumor site, resulting in reduced tumor growth and increased apoptosis. This case study illustrated the promise of miRNA-based therapies in pediatric cancers (Welch et al., 2007).
- MiR-122 in Hepatitis C Virus (HCV) Infection: MiR-122 is a liver-specific miRNA that plays a role in HCV replication. Case studies have investigated the use of miR-122 inhibitors to block HCV replication, showing potential for miRNA-based antiviral therapy (Janssen et al., 2013).

These case studies underscore the diverse applications of miRNA-based therapies in cancer and other diseases, providing valuable insights into their clinical utility.

9. Technological Advancements in miRNA Research

Technological advancements have revolutionized the field of microRNA (miRNA) research, enabling more comprehensive and precise analysis of miRNA expression and function. Here are some key advancements:

- Next-Generation Sequencing (NGS): NGS technologies have transformed miRNA profiling. Researchers can now conduct deep sequencing of miRNAs from various biological samples. This approach, known as small RNA sequencing, provides high-throughput, quantitative data on miRNA expression. It allows for the discovery of novel miRNAs, assessment of miRNA isoforms, and differential expression analysis. NGS has greatly expanded our understanding of the miRNAome and its role in health and disease.
- Single-Cell Sequencing: Single-cell RNA sequencing (scRNA-seq) has been adapted to miRNA research, enabling the profiling of miRNAs at the single-cell level. This technology has revealed miRNA heterogeneity within cell populations, shedding light on the regulatory complexity of miRNAs in cellular processes.

- Cryo-Electron Microscopy (Cryo-EM): Cryo-EM has been used to study the structural biology of miRNA-loaded RNA-induced silencing complexes (miRISCs). This technology provides insights into the conformation and interactions of miRNAs with their target mRNAs and Argonaute proteins, deepening our understanding of miRNA-mediated gene regulation.

10. Bioinformatics Tools for MiRNA Target Prediction and Functional Analysis

Bioinformatics tools have become indispensable for miRNA research, offering powerful methods for miRNA target prediction and functional analysis:

- Target Prediction Algorithms: Several computational algorithms, such as TargetScan, miRanda, and PicTar, predict miRNA target sites within mRNA sequences based on seed sequence complementarity and other features. These tools have evolved to incorporate additional factors, including target site accessibility and conservation, enhancing the accuracy of predictions.
- Functional Enrichment Analysis: Bioinformatics platforms like miRWalk and DIANA-miRPath enable researchers to perform functional enrichment analysis of miRNA target genes. These tools identify pathways and biological processes enriched among the predicted target genes, providing insights into miRNA function.
- Integrated Databases: Comprehensive miRNA databases, such as miRBase and miRTarBase, offer curated collections of miRNA sequences, target interactions, and experimental evidence. These resources facilitate data mining and validation of miRNA-related findings.
- Network Analysis: Network-based approaches, such as Cytoscape and miRNA-centered networks, allow researchers to visualize and analyze miRNA-mRNA interactions within complex regulatory networks. Network analysis aids in understanding the global impact of miRNAs on cellular processes.

11. miRNAs and Drug Resistance

MicroRNAs (miRNAs) play a significant role in mediating drug resistance in cancer, including resistance to chemotherapy and radiotherapy. Here's an overview of their involvement:

- Chemotherapy Resistance: MiRNAs can contribute to chemotherapy resistance by regulating genes involved in drug response and cell survival. For example, miR-21 is often upregulated in drug-resistant cancer cells and can target tumor suppressor genes, leading to enhanced cell survival and resistance to chemotherapy agents. Similarly, miR-34a, a tumor suppressor miRNA, is downregulated in drug-resistant cells, allowing for the overexpression of anti-apoptotic genes.

- Radiotherapy Resistance: MiRNAs can also influence radiotherapy resistance by affecting DNA repair mechanisms and cellular responses to radiation-induced damage. For instance, miR-24-3p has been implicated in radioresistance by targeting genes involved in DNA repair. Downregulation of miR-24-3p can enhance the repair of radiation-induced DNA damage, promoting cell survival.

12. Strategies to Overcome MiRNA-Related Drug Resistance

Addressing miRNA-related drug resistance is a complex challenge, but several strategies are being explored:

- MiRNA Mimics and Inhibitors: MiRNA-based therapeutics can be employed to modulate the expression of specific miRNAs involved in drug resistance. MiRNA mimics can restore the function of tumor suppressor miRNAs, while miRNA inhibitors (antimiRs) can block the activity of oncomiRs. These approaches aim to sensitize drug-resistant cells to chemotherapy or radiotherapy.
- Combination Therapies: Combining miRNA-based therapeutics with conventional cancer treatments is a promising strategy. This approach involves the simultaneous use of chemotherapy, radiotherapy, or targeted therapies with miRNA modulators to overcome resistance. For example, miRNA mimics can be co-administered with chemotherapy agents to enhance drug efficacy.
- Nanoparticle-Based Delivery: Nanoparticle-based delivery systems can improve the targeted delivery of miRNA-based therapeutics to tumor cells. These nanoparticles protect miRNAs from degradation and facilitate their uptake by drug-resistant cancer cells. Enhanced delivery can enhance the therapeutic effect of miRNA modulators.
- Personalized Medicine: Personalized medicine approaches involve the identification of miRNA profiles in individual patients to tailor treatment strategies. Analyzing miRNA expression patterns can guide the selection of the most effective therapies, including miRNA-based interventions, for patients with drug-resistant cancers.

13. Conclusion

In conclusion, the field of microRNA (miRNA) research is advancing at a rapid pace, driven by emerging trends and accompanied by intriguing challenges. The future of miRNA research promises to be both exciting and transformative. One of the notable trends is the exploration of single-cell miRNA profiling, which allows researchers to dissect the intricate heterogeneity of miRNA expression within tissues and cell populations. This approach offers unprecedented insights into the roles of specific miRNAs in individual cells, unveiling their contributions to diverse biological processes. Extracellular vesicle (EV) miRNAs have also emerged as key players in intercellular communication. Understanding the cargo and functions of miRNAs within EVs is a burgeoning area of research with implications in diagnostics and therapeutics, particularly in cancer. Interactions between miRNAs and long non-coding RNAs (lncRNAs) have introduced a layer of complexity in miRNA regulation, warranting further investigation into these regulatory networks. However, miRNA research is not without its challenges.

Unresolved questions persist, such as the functional validation of novel miRNAs, which underscores the need for continued exploration of miRNA functions in health and disease. Clinical translation of miRNA-based therapeutics faces hurdles related to delivery and safety, necessitating ongoing efforts to optimize these therapies for patient benefit. Long-term effects of miRNA manipulation and epitranscriptomic regulation of miRNAs are also areas of interest for future research. As the field of miRNA research continues to evolve, it holds immense potential to impact diagnostics, therapeutics, and our fundamental understanding of gene regulation. The dynamic nature of miRNA biology ensures that exciting discoveries lie ahead, driving innovation and transformative changes in the biomedical landscape. Researchers worldwide are poised to unravel the mysteries of miRNAs and harness their potential for the betterment of human health.

14. References

1. Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology.
2. Bartel, D. P. (2018). Metazoan MicroRNAs. Cell.
3. Li, Z., & Rana, T. M. (2014). Therapeutic targeting of microRNAs: Current status and future challenges. Nature Reviews Drug Discovery.
4. Hayes, J., Peruzzi, P. P., & Lawler, S. (2014). MicroRNAs in cancer: Biomarkers, functions and therapy. Trends in Molecular Medicine.
5. Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nature Reviews Clinical Oncology.
6. Lin, S., Gregory, R. I. (2015). MicroRNA biogenesis pathways in cancer. Nature Reviews Cancer.
7. Schwarzenbach, H., & Pantel, K. (2015). Circulating DNA as biomarker in breast cancer. Breast Cancer Research.
8. Hanna, J., & Hossain, G. S. (2019). "Killing the Messenger: New Strategies to Eliminate or Modulate MicroRNA Function." In RNA Therapeutics (pp. 243-266). Humana, New York, NY.
9. Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery, 16(3), 203-222.
10. Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., & Croce, C. M. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences, 102(39), 13944-13949.
11. Welch, C., Chen, Y., & Stallings, R. L. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene, 26(34), 5017-5022.
12. Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., & de Knegt, R. J. (2013). Treatment of HCV infection by targeting microRNA. New England Journal of Medicine, 368(18), 1685-1694.
13. Bartel, D. P. (2018). Metazoan MicroRNAs. Cell, 173(1), 20-51.

14. Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews Drug Discovery, 16(3), 203-222.
15. Esteller, M. (2011). Non-coding RNAs in human disease. Nature Reviews Genetics, 12(12), 861-874.
16. Garofalo, M., Croce, C. M. (2011). "microRNAs: Master regulators as potential therapeutics in cancer." Annual Review of Pharmacology and Toxicology, 51, 25-43.
17. Zhang, X., Zeng, J., Zhou, M., Li, B., Zhang, Y., & Huang, T. (2020). Exosome-derived microRNA-24-3p attenuates radiation-induced injury in cardiomyocyte HL-1 cells by targeting BCL2L11. Experimental and Therapeutic Medicine, 19(3), 1738-1746.
18. Song, L., Liu, S., Zhang, L., Yao, H., Gao, F., Xu, D., & Qiu, Z. (2010). MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt-mTOR signaling pathway. Oncotarget, 6(11), 4147-4164.
19. Stefani, G., & Slack, F. J. (2008). Small non-coding RNAs in animal development. Nature Reviews Molecular Cell Biology, 9(3), 219-230.
20. Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology, 9(6), 654-659.
21. Rinn, J. L., & Chang, H. Y. (2012). Genome regulation by long noncoding RNAs. Annual Review of Biochemistry, 81, 145-166.
22. Mendell, J. T., & Olson, E. N. (2012). MicroRNAs in stress signaling and human disease. Cell, 148(6), 1172-1187.
23. Gebert, L. F. R., & MacRae, I. J. (2019). Regulation of microRNA function in animals. Nature Reviews Molecular Cell Biology, 20(1), 21-37.
24. Mendell, J. T., & Olson, E. N. (2012). MicroRNAs in stress signaling and human disease. Cell, 148(6), 1172-1187.
25. Alarcón, C. R., & Goodarzi, H. (2018). RNA Modifying Proteins and RNA Modification Marks: Shadows of the Epitranscriptome. Wiley Interdisciplinary Reviews: RNA, 9(1), e1481.